CBD Life Sciences Inc (PK) (CBDL) News

CBDL has great SS in OTC stocks, no need R/S

Share Structure
Market Cap Market Cap
1,197,255
12/20/2024
Authorized Shares
6,500,000,000
12/20/2024
Outstanding Shares
2,993,138,610
12/20/2024
Restricted
1,507,966,095
12/20/2024
Unrestricted
1,485,172,515
12/20/2024
Held at DTC
1,483,327,260
12/20/2024
Float
134,721,527
04/24/2024
Par Value
0.0001

CBDL is a best stock to own. in 2025 NO r/s, no dilution, revenue increasing fast. Good company in good industry.PPS is on bottom, very undervalued, PPS has huge potential to going up. next year PPS can be reached multi pennies for sure.

CBDL is preparing for 2025

It's going like like the past. As it keep ticking down. Once it got to .00001 it never moved. Then we saw the r/s and were it is now. IT all the same massive dilution.

Wrong. Beware massive dilution scam. All shares sold are dilution at these levels. Like people before this r/s. Dilution and r/s wiped them out. No one is up at these levels after the r/s. Anyone buying will lose it all like they did. It is being diluted and dropping the same as before last r/s.

CBDL is a next year's winner, 0.0004 is a cheap PPS to buy.

0.0004 is a good buy for next year going up to making big money. Company revenue increasing, no No need dilution

Lol sure. What do you think is filling buys at these levels? Dilution.

At this rate of dilution it will not be long before .00001 again. The huge volume for 2 days did not move it because all dilution. This is just like before. Do r/s, increase a/s by billions. See it drop. Then have short lived spike and back down. Then keep going down until .00001. It a rinse and repeat again. Buying this is throwing money away. The revenues filed are 167,000. The dilution for 4 years billions. They get rich selling shares to suckers not products.

Wow over 100 million in dilution so far. The rate they are going. They will sell all the new shares 4.5 billion A/S after the r/s. People again will learn. The massive dilution never ends. It will end up like before. .0001 and never move off it. They get rich selling shares not CBD. Rinse and repeat. CBD is a very competitive market. That is why after 4 years. That last income statement showed 167,000 in sales. In that time they have sold billions and billions of shares. Like I said they get rich selling shares to suckers. After this r/s new suckers.

Big products lol. The last income statement showed 167,000 in sales. Tiny vs all the billions in dilution.

make no sense, they sell big products

$CBDL They didn't reduce shares at all and this news is Deceiving. They reduce shares on the authorize and that shares issued already. That don't mean squat they can always raise it back up. The stock was getting weak and they needed news as they always do. News so they can sell more stock.

HUGE NEWS - 3.5 Billion Share Reduction
Dated Today 12/18/2024
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Announces-35-Billion-Share-Reduction-From-the-Authorization?id=462712

.001++ Potential $$$$$

Big share reduction and it's already taken effect if you check OTCmarkets 

CBD Life Sciences Inc. (CBDL) Announces 3.5 Billion Share Reduction From the AuthorizationPress Release | 12/18/2024

Demonstrating shareholder confidence, CBDL commits to repurchasing 10% of revenue quarterly.

SCOTTSDALE, AZ / ACCESSWIRE / December 18, 2024 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD and wellness industry, is thrilled to announce a significant milestone in its ongoing commitment to delivering shareholder value. The company has successfully reduced its authorized share count by a staggering 3.5 billion shares. This strategic move underscores CBDL's dedication to strengthening its financial position and enhancing shareholder equity.

This monumental share reduction marks a pivotal moment for CBDL as it continues to streamline its capital structure and build trust with investors. By decreasing the number of authorized shares, CBDL aims to reduce dilution, increase stock value, and solidify its reputation as a company that prioritizes its shareholders' interests. This is a clear signal to the market that CBDL is committed to fostering sustainable growth while putting its shareholders first.

Key Benefits of the Share Reduction Initiative:

Enhanced Stock Value: By significantly reducing authorized shares, CBDL positions itself to offer greater value to shareholders, reflecting positively on stock performance and market sentiment.

Increased Investor Confidence: Demonstrates CBDL's long-term commitment to aligning with shareholder goals and building a robust and transparent financial framework.

Strategic Financial Management: Signals a disciplined approach to capital management, paving the way for stronger financial performance and long-term profitability.

In addition to this bold initiative, CBDL has announced a groundbreaking new policy to repurchase 10% of its revenue in stock each quarter. This progressive strategy not only underscores CBDL's confidence in its business model but also reinforces its dedication to returning value directly to shareholders. "By reinvesting in our own stock, we're showing that we're not just talking about growth-we're actively creating it," said Lisa Nelson, President and CEO of CBDL. "This move reflects our optimism about the future and our unwavering commitment to maximizing shareholder value."

The share reduction comes on the heels of an impressive 1405.46% revenue growth since February 2024, driven by the company's expanding product line and strategic retail partnerships, including Walmart Marketplace. This explosive growth highlights the success of CBDL's innovative product offerings, such as the highly sought-after 3000MG Pain Relief Cream and Delta 8 Gummies. These products are not only meeting the needs of a rapidly growing market but also setting the standard for quality and effectiveness in the CBD industry.

CBDL's leadership continues to pave the way for an exciting future. The company's visionary approach and relentless focus on innovation, sustainability, and customer satisfaction have positioned it as a trailblazer in the wellness sector. The decision to reduce shares and repurchase stock underscores the confidence CBDL's management has in its strategic direction and its ability to deliver tangible results for investors.

As CBDL looks ahead, the company remains steadfast in its mission to revolutionize the CBD industry with cutting-edge products and a commitment to excellence. With a robust pipeline of initiatives, including new product launches and expanded retail partnerships, the future is brighter than ever for CBD Life Sciences Inc.

About CBD Life Sciences Inc. CBD Life Sciences Inc. (OTC: CBDL) is at the forefront of the CBD and wellness revolution. The company offers a diverse range of high-quality CBD-based products, leveraging advanced nanotechnology and sustainable practices to deliver superior solutions for consumers and businesses alike. With a focus on innovation and investor confidence, CBDL is redefining the future of wellness.

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

SOURCE: CBD Life Sciences Inc.


View the original press release on accesswire.com
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Announces-35-Billion-Share-Reduction-From-the-Authorization?id=462712

Good Morning $CBDL

$CBDL CBD Life Sciences Inc. (CBDL) Announces 3.5 Billion Share Reduction From the Authorization

https://www.accesswire.com/956484/cbd-life-sciences-inc-cbdl-announces-35-billion-share-reduction-from-the-authorization

Demonstrating shareholder confidence, CBDL commits to repurchasing 10% of revenue quarterly.

SCOTTSDALE, AZ / ACCESSWIRE / December 18, 2024 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD and wellness industry, is thrilled to announce a significant milestone in its ongoing commitment to delivering shareholder value. The company has successfully reduced its authorized share count by a staggering 3.5 billion shares. This strategic move underscores CBDL's dedication to strengthening its financial position and enhancing shareholder equity.

This monumental share reduction marks a pivotal moment for CBDL as it continues to streamline its capital structure and build trust with investors. By decreasing the number of authorized shares, CBDL aims to reduce dilution, increase stock value, and solidify its reputation as a company that prioritizes its shareholders' interests. This is a clear signal to the market that CBDL is committed to fostering sustainable growth while putting its shareholders first.

Key Benefits of the Share Reduction Initiative:

Enhanced Stock Value: By significantly reducing authorized shares, CBDL positions itself to offer greater value to shareholders, reflecting positively on stock performance and market sentiment.

Increased Investor Confidence: Demonstrates CBDL's long-term commitment to aligning with shareholder goals and building a robust and transparent financial framework.

Strategic Financial Management: Signals a disciplined approach to capital management, paving the way for stronger financial performance and long-term profitability.

In addition to this bold initiative, CBDL has announced a groundbreaking new policy to repurchase 10% of its revenue in stock each quarter. This progressive strategy not only underscores CBDL's confidence in its business model but also reinforces its dedication to returning value directly to shareholders. "By reinvesting in our own stock, we're showing that we're not just talking about growth-we're actively creating it," said Lisa Nelson, President and CEO of CBDL. "This move reflects our optimism about the future and our unwavering commitment to maximizing shareholder value."

The share reduction comes on the heels of an impressive 1405.46% revenue growth since February 2024, driven by the company's expanding product line and strategic retail partnerships, including Walmart Marketplace. This explosive growth highlights the success of CBDL's innovative product offerings, such as the highly sought-after 3000MG Pain Relief Cream and Delta 8 Gummies. These products are not only meeting the needs of a rapidly growing market but also setting the standard for quality and effectiveness in the CBD industry.

CBDL's leadership continues to pave the way for an exciting future. The company's visionary approach and relentless focus on innovation, sustainability, and customer satisfaction have positioned it as a trailblazer in the wellness sector. The decision to reduce shares and repurchase stock underscores the confidence CBDL's management has in its strategic direction and its ability to deliver tangible results for investors.

As CBDL looks ahead, the company remains steadfast in its mission to revolutionize the CBD industry with cutting-edge products and a commitment to excellence. With a robust pipeline of initiatives, including new product launches and expanded retail partnerships, the future is brighter than ever for CBD Life Sciences Inc.

The people by the dilution shares. Not very smart with track record here. The shares sold daily at these levels all dilution. When it gets stuck again at .00001 and done. They will lose like all shareholders before this r/s have. They will sell all 4.5 billion they increase the a/s to after the r/s.

$CBDL I just checked in on this thing and dilution dilution dilution. Mennie double prints with market maker OTCN plan on the ask. Looks like the Nelsons need some Christmas money but then again they're always need money. Couple years ago when they did this they bought a multimillion dollar houseIn Scottsdale Arizona.

Sure but this one. When dilution never ends. Is not dormant. It has good volume. Dilution is and always has been the problem. Why? They get rich selling shares not CBD.

Not entirely. Some stocks remain dormant.

I said for years the dilution will never stop. Why? They get rich selling shares not CBD. It will end up at .00001 and done yet again. No shareholders have a gain at these levels. Of course dilution like before is filling buys. All anyone has to do is look at all the dilution since 2021. To know it is not very smart to buy shares. They still have billions to sell.

There is an active Reg A selling stock at .0006. That is why the stock will not move. Anyone who buys this is throwing their money away. The Nelsons will not let this move. Too lucrative of a game 

Not this one. They have 4.5 billion shares to dump. Same as before. It will end up like before at .00001. Then like before stuck until next r/s.

When the OTC flash flood hits, all boats will rise, every dog has it's day in the OTC!

A lot of PR's. Yet after 4 years of massive dilution that never ends. Look at last income statement. 167,000 in sales. All this is all talk to sell billions of more shares. They are a no body in the CBD market. Every day they sell new shares to suckers.

The OTC is dead.

CBD Life Sciences Inc. (CBDL) Looking to Acquire a Cannabis Growth License in North Las VegasPress Release | 12/11/2024

Target Acquisition Valued at $10 Million with Projected 2025 Gross Revenue of $5 Million, Positioning CBDL for Explosive Growth in Nevada's Burgeoning Cannabis Market

SCOTTSDALE, AZ / ACCESSWIRE / December 11, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in CBD innovation, announces its intent to acquire a cannabis growth license in North Las Vegas, a move that could serve as a transformative step in the company's evolution. With a target business value of $10 million and a projected $5 million in gross revenue by 2025, this acquisition positions CBDL at the forefront of Nevada's thriving cannabis cultivation market, which is projected to surpass $1.3 billion by 2025.

Expanding beyond its already successful CBD product portfolio, this acquisition will enable CBDL to enter the cannabis cultivation and distribution space, capitalizing on the robust demand for high-quality cannabis products in Nevada and across the nation. This strategic pivot is set to unlock significant revenue potential while solidifying the company's status as a dual-market powerhouse in both CBD and cannabis.

The Nevada Cannabis Market: A Strategic Opportunity

Nevada is one of the most dynamic cannabis markets in the United States, driven by strong consumer demand, progressive regulations, and a booming tourism industry. North Las Vegas, located within Clark County, offers a unique advantage for cannabis cultivation due to its proximity to Las Vegas' 40+ million annual tourists and access to key distribution channels. With legalization trends continuing to sweep the nation, Nevada's cannabis market remains a critical growth hub for companies like CBDL.

Securing a cannabis growth license in this region offers unparalleled potential. Cannabis cultivation facilities in Nevada have demonstrated the ability to generate annual revenues ranging from $1.5 million to $5 million, depending on scale and efficiency. For CBDL, this venture could create new revenue streams and provide significant competitive advantages in an increasingly crowded marketplace.

Diversifying Revenue and Strengthening Market Position

The cannabis growth license acquisition aligns with CBDL's long-term strategy of diversification and growth. In addition to providing a new revenue channel, this venture allows the company to vertically integrate its operations, controlling production quality while reducing costs. Vertical integration is particularly advantageous in the cannabis industry, where consistency, compliance, and quality are key differentiators.

By producing cannabis in-house, CBDL gains greater control over the supply chain and opens doors to additional high-margin opportunities, including:

White-label partnerships with other cannabis brands.

Direct-to-consumer sales through dispensaries.

Product development leveraging CBDL's expertise in formulating premium CBD products.

This expansion also strengthens CBDL's ability to cater to diverse consumer preferences, from recreational cannabis users to medical patients seeking relief through high-quality cannabis products.

Revenue Projections That Excite

As part of this expansion, CBDL anticipates a substantial increase in its revenue trajectory. The company's current growth momentum, evidenced by a 1,405.46% revenue increase since February 2024, underscores its ability to scale effectively and capitalize on new opportunities. The projected $5 million in gross revenue from this cannabis growth license by 2025 could propel CBDL to new heights, allowing it to reinvest in operations, marketing, and product innovation.

Additionally, the Nevada cannabis market benefits from one of the most business-friendly taxation systems in the country, providing further incentives for long-term profitability. Coupled with its flourishing tourism industry and expanding local customer base, this acquisition represents a near-perfect synergy between market opportunity and company capabilities.

Endless Possibilities for Growth and Innovation

The cannabis industry is evolving at an unprecedented pace, with significant advancements in cultivation technology, product innovation, and consumer awareness. By establishing a foothold in North Las Vegas, CBDL can leverage these trends to develop cutting-edge products that appeal to a wide range of consumers. The potential for partnerships with dispensaries, research institutions, and wellness companies further underscores the limitless growth opportunities this acquisition presents.

"This is not just another step for CBD Life Sciences Inc. - it's a leap toward redefining our company's future," said Lisa Nelson, President and CEO of CBDL. "With a cannabis growth license in North Las Vegas, we are positioned to accelerate our growth, diversify our portfolio, and deliver unmatched value to our shareholders."

Looking Ahead: A Bright Future for CBDL

CBDL's entrance into the cannabis cultivation market represents a monumental shift in its operational strategy, but it's only the beginning. As the company continues to explore expansion opportunities in Nevada and other high-growth regions, shareholders and investors can expect exciting updates in the months ahead.

The acquisition of this growth license is more than a business move - it's a testament to CBDL's commitment to innovation, growth, and shareholder value. With the cannabis and CBD markets projected to reach record-breaking revenues in the coming years, CBDL is positioning itself as a trailblazer in the wellness industry.

For more information, please visit CBD Life Sciences Inc.

About CBD Life Sciences Inc.

CBD Life Sciences Inc. (OTC:CBDL) is a leader in the CBD and wellness industries, specializing in premium CBD products and innovative solutions. With a proven track record of growth and a forward-thinking approach, CBDL continues to expand its presence in emerging markets, driving shareholder value and industry leadership.

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

Related Images

SOURCE: CBD Life Sciences Inc.
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Looking-to-Acquire-a-Cannabis-Growth-License-in-North-Las-Vegas?id=461963

Good Morning $CBDL

$CBDL CBD Life Sciences Inc. (CBDL) Looking to Acquire a Cannabis Growth License in North Las Vegas

https://www.accesswire.com/952724/cbd-life-sciences-inc-cbdl-looking-to-acquire-a-cannabis-growth-license-in-north-las-vegas

Target Acquisition Valued at $10 Million with Projected 2025 Gross Revenue of $5 Million, Positioning CBDL for Explosive Growth in Nevada's Burgeoning Cannabis Market

SCOTTSDALE, AZ / ACCESSWIRE / December 11, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in CBD innovation, announces its intent to acquire a cannabis growth license in North Las Vegas, a move that could serve as a transformative step in the company's evolution. With a target business value of $10 million and a projected $5 million in gross revenue by 2025, this acquisition positions CBDL at the forefront of Nevada's thriving cannabis cultivation market, which is projected to surpass $1.3 billion by 2025.

Expanding beyond its already successful CBD product portfolio, this acquisition will enable CBDL to enter the cannabis cultivation and distribution space, capitalizing on the robust demand for high-quality cannabis products in Nevada and across the nation. This strategic pivot is set to unlock significant revenue potential while solidifying the company's status as a dual-market powerhouse in both CBD and cannabis.

The Nevada Cannabis Market: A Strategic Opportunity

Nevada is one of the most dynamic cannabis markets in the United States, driven by strong consumer demand, progressive regulations, and a booming tourism industry. North Las Vegas, located within Clark County, offers a unique advantage for cannabis cultivation due to its proximity to Las Vegas' 40+ million annual tourists and access to key distribution channels. With legalization trends continuing to sweep the nation, Nevada's cannabis market remains a critical growth hub for companies like CBDL.

Securing a cannabis growth license in this region offers unparalleled potential. Cannabis cultivation facilities in Nevada have demonstrated the ability to generate annual revenues ranging from $1.5 million to $5 million, depending on scale and efficiency. For CBDL, this venture could create new revenue streams and provide significant competitive advantages in an increasingly crowded marketplace.

Diversifying Revenue and Strengthening Market Position

The cannabis growth license acquisition aligns with CBDL's long-term strategy of diversification and growth. In addition to providing a new revenue channel, this venture allows the company to vertically integrate its operations, controlling production quality while reducing costs. Vertical integration is particularly advantageous in the cannabis industry, where consistency, compliance, and quality are key differentiators.

By producing cannabis in-house, CBDL gains greater control over the supply chain and opens doors to additional high-margin opportunities, including:

White-label partnerships with other cannabis brands.

Direct-to-consumer sales through dispensaries.

Product development leveraging CBDL's expertise in formulating premium CBD products.

This expansion also strengthens CBDL's ability to cater to diverse consumer preferences, from recreational cannabis users to medical patients seeking relief through high-quality cannabis products.

Revenue Projections That Excite

As part of this expansion, CBDL anticipates a substantial increase in its revenue trajectory. The company's current growth momentum, evidenced by a 1,405.46% revenue increase since February 2024, underscores its ability to scale effectively and capitalize on new opportunities. The projected $5 million in gross revenue from this cannabis growth license by 2025 could propel CBDL to new heights, allowing it to reinvest in operations, marketing, and product innovation.

Additionally, the Nevada cannabis market benefits from one of the most business-friendly taxation systems in the country, providing further incentives for long-term profitability. Coupled with its flourishing tourism industry and expanding local customer base, this acquisition represents a near-perfect synergy between market opportunity and company capabilities.

Endless Possibilities for Growth and Innovation

The cannabis industry is evolving at an unprecedented pace, with significant advancements in cultivation technology, product innovation, and consumer awareness. By establishing a foothold in North Las Vegas, CBDL can leverage these trends to develop cutting-edge products that appeal to a wide range of consumers. The potential for partnerships with dispensaries, research institutions, and wellness companies further underscores the limitless growth opportunities this acquisition presents.

"This is not just another step for CBD Life Sciences Inc. - it's a leap toward redefining our company's future," said Lisa Nelson, President and CEO of CBDL. "With a cannabis growth license in North Las Vegas, we are positioned to accelerate our growth, diversify our portfolio, and deliver unmatched value to our shareholders."

Looking Ahead: A Bright Future for CBDL

CBDL's entrance into the cannabis cultivation market represents a monumental shift in its operational strategy, but it's only the beginning. As the company continues to explore expansion opportunities in Nevada and other high-growth regions, shareholders and investors can expect exciting updates in the months ahead.

The acquisition of this growth license is more than a business move - it's a testament to CBDL's commitment to innovation, growth, and shareholder value. With the cannabis and CBD markets projected to reach record-breaking revenues in the coming years, CBDL is positioning itself as a trailblazer in the wellness industry.

For more information, please visit CBD Life Sciences Inc.

Goon
I have to agree with you on this.one .

Really. So they can sell another billion shares to suckers. Some just never learn.

BIG OPPORTUNITY COMING NEXT WEEK, STAY TUNED $CBDL

Another 16 million in dilution.

For good reason. It still tiny revenues vs billions in dilution. At these levels. Only shares for sale are dilution. 4.5 billion a/s for sale. Dilution has never ended here and never will. They make a lot more selling shares and have now for 4 years.

tweet out "Good morning $CBDL shareholders! Expect next week to one of our biggest yet! The Armed Forces deal should be done! 

We’re also close to reducing the authorized share count to increase shareholder value! Expect big news next week!"

$CBDL huge move is imminent folks. Load and hold. https://x.com/CBDL_StockOTC/status/1865037351228944586

why news out PPS didn't going up? only reason is that PR only say revenue increasing good percent, but not too much number.which they didn't say..

Once again when they dilute billions so it still overvalued. As for this deal. I will believe it when we see it show up on the income statement.

News Alerts https://x.com/CBDL_StockOTC/status/1864738855867289869

Notice they never provide a dollar amount. That is because last filing showed revenues of 167,000.That means revenues still tiny vs billions in dilution. Then do they make profit? It be tiny as well. The way they sell new shares. They could never sell enough CBD to justify that dilution. They make money selling shares. Billions of them not CBD. They have done this since Late 2020 and still are after r/s. At they levels it's new shares filling buys every day.

OTCMKTS: $CBDL Breaking News🚨

CBD Life Sciences Inc. reports a 622% revenue increase from June to November 2024, marking a 1,405% YTD growth driven by strategic launches and market expansion.

$CBDL CBD Life Sciences, Inc. (CBDL) Reports Stunning 622% Revenue Growth From June to November 2024

https://www.accesswire.com/950416/cbd-life-sciences-inc-cbdl-reports-stunning-622-revenue-growth-from-june-to-november-2024

Exploding with momentum: CBDL shatters records with 622% revenue growth in five months, propelling to a 1,405% year-to-date increase-a game-changer in the CBD industry.

SCOTTSDALE, ARIZONA / ACCESSWIRE / December 5, 2024 / CBD Life Sciences, Inc. (CBDL), a leading innovator in the CBD industry, is proud to announce an extraordinary 622% increase in revenue over the five-month period from June to November 2024. This milestone reflects the company's dedication to strategic growth, innovative product development, and expanding market reach.

This revenue surge follows a banner year for CBDL, with year-to-date growth reaching unprecedented levels. Since February 2024, CBDL has experienced a staggering 1,405.46% increase in revenue, further solidifying its position as a dominant force in the CBD and wellness sectors. This success is a testament to CBDL's strategic vision and ability to adapt to the rapidly growing demand for cannabidiol products across various markets.

Key Drivers of Success

Potential Dispensary Acquisition: CBDL has signed a Letter of Intent (LOI) for a strategic partnership involving a cannabis dispensary, opening doors to a new revenue stream and positioning the company as a frontrunner in the retail cannabis market. This move demonstrates CBDL's commitment to seizing high-value opportunities and expanding its influence in the cannabis sector.

Strategic Product Launches: CBDL's product development pipeline has been a critical driver of growth. Flagship products like the Delta-8 Gummies, Pain Relief Cream, Mellow Mornings Nano CBD Coffee Creamer and the veterinarian-designed CBD Horse Paste have captured the attention of consumers and retailers alike, setting new benchmarks for product efficacy and quality.

Retail Expansion: The company's bold move into Walmart Marketplace has significantly expanded its domestic footprint, while plans to launch on Alibaba pave the way for international growth. These initiatives align with CBDL's mission to make its top-tier products accessible to a global audience.

Innovative Science and Technology: CBDL's commitment to leveraging cutting-edge technology, such as nanotechnology, ensures that its products deliver maximum bioavailability and effectiveness. The development of mushroom-based supplements targeting stress reduction and cognitive health showcases the company's ability to diversify its portfolio in response to emerging consumer trends.

Operational Excellence: By streamlining its supply chain and optimizing production processes, CBDL has not only scaled operations but also improved profit margins, ensuring sustainable growth.

Leadership Perspective

Lisa Nelson, President and CEO of CBD Life Sciences, Inc., remarked, "Our 622% revenue growth from June to November is not just a number; it's a reflection of the trust our customers and partners place in us. This achievement is a direct result of our team's unwavering commitment to excellence. As we continue to innovate and enter new markets, our shareholders can anticipate even greater returns on their investment."

Industry Outlook

The global CBD market, which was valued at USD 7.42 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 16.8% from 2024 to 2030. CBDL's robust growth trajectory positions the company as a leader in this booming sector. The market's rapid expansion offers a unique opportunity for investors to capitalize on what is poised to become one of the most lucrative industries in the health and wellness space.

Future Initiatives

CBDL remains steadfast in its commitment to:

Expanding Partnerships: Collaborating with global retailers and exploring strategic alliances to widen distribution networks.

Driving Innovation: Investing in research and development to create groundbreaking products that meet evolving consumer needs.

Enhancing Shareholder Value: Maintaining transparency and delivering consistent financial performance to build investor confidence.

Why Invest in CBDL?

With an impressive track record of growth, a diversified product portfolio, and a strategic roadmap for expansion, CBDL offers an unparalleled investment opportunity. The company's focus on high-growth markets, combined with its operational efficiencies, ensures it is well-positioned to deliver long-term value.

CBDL no dilution since 11/12/2024, O/S shares is 2,782027,499, until today 12/03/2024, no change. CBDL is a very under- valued stock, Its MC only $1,669,216. It will take off any day soon.

What nonsense. They sell shares. Billions over and over. Sale of product tiny. Like I said this will end up diluted back to .0001 again. They could never sell enough CBD to ever justify all the dilution since 2020. It's so over valued even if they sold millions and if they ever make a profit. They make money selling shares to fools not cbd. Has been that way for 4 years. Your nonsense will not change that.

This is a very undervalued stock in OTC markets. Compare the other OTC stocks, this one have much better SS. Revenue has huge potential to increasing, CBDL will break out 0.001 very soon.

Right now it's long way from that. Revenues $167,000 per last income statement. After 4 years and massive dilution that how small the revenues are. CBD is very competitive market. Even if they sold millions. When the o/s the will be billions again. It is still over valued. Who do people think is selling share every day at these levels? The company is.

OTCMKTS: CBDL shareholders! Company recently announced new product projected to do $3mil revenue in the first year! The LOI is closed for the $8mil revenue dispensary.